Revenue Recognition and Accounts Receivable - Disaggregation of Revenue by Key Products (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Net sales	$ 15,388.4	$ 16,218.1	$ 17,813.6
Lipitor ®
Disaggregation of Revenue [Line Items]
Net sales	1,559.3	1,635.2	1,663.2
Norvasc ®
Disaggregation of Revenue [Line Items]
Net sales	732.4	775.1	824.7
Lyrica ®
Disaggregation of Revenue [Line Items]
Net sales	556.5	623.8	728.5
EpiPen® Auto-Injectors
Disaggregation of Revenue [Line Items]
Net sales	442.2	378.0	391.7
Viagra ®
Disaggregation of Revenue [Line Items]
Net sales	428.8	458.9	533.8
Celebrex ®
Disaggregation of Revenue [Line Items]
Net sales	330.6	338.1	344.4
Creon ®
Disaggregation of Revenue [Line Items]
Net sales	304.9	304.0	309.8
Effexor ®
Disaggregation of Revenue [Line Items]
Net sales	262.9	279.6	316.8
Zoloft ®
Disaggregation of Revenue [Line Items]
Net sales	235.7	246.2	284.3
Xalabrands
Disaggregation of Revenue [Line Items]
Net sales	193.2	195.1	226.0
Yupelri ®
Disaggregation of Revenue [Line Items]
Net sales	220.8	202.1	161.9
Dymista ®
Disaggregation of Revenue [Line Items]
Net sales	200.0	179.8	168.0
Influvac ®
Disaggregation of Revenue [Line Items]
Net sales	192.4	225.5	299.3
Amitiza ®
Disaggregation of Revenue [Line Items]
Net sales	157.0	167.9	201.5
Xanax ®
Disaggregation of Revenue [Line Items]
Net sales	$ 154.8	$ 156.5	$ 185.9